Építés alatt – nem éles oldal
Belépés
Résztvevőt keres3. fázis

Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Embolism

A legfontosabb adatok

Ki végzi
Supergene, LLC
Hol
Oroszország24 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
486 fő, tervezett
Kezdés
2024. máj. 23.
Várható befejezés
2028. dec. 1.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Non-immunogenic recombinant staphylokinase
  • Placebo
A regiszteradat frissítve
2025. december 5.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with a blood clot in the lungs (pulmonary embolism) at intermediate high risk and normal blood pressure. It compares one quick injection of non-immunogenic recombinant staphylokinase with a placebo.

Életkor
18 years and over.
Nem
Men and women.
A betegség stádiuma
Intermediate high-risk pulmonary embolism confirmed by a CT scan of the lung arteries (CTPA), within two weeks of first symptoms. The right side of the heart must be strained (RV/LV ratio more than 1.0 on CTPA). There must also be one sign of higher risk: systolic blood pressure less than 110 mm Hg but not less than 90 mm Hg for more than 15 minutes; or breathing rate more than 20 per minute or SpO2 less than 90% without oxygen; or chronic heart failure with ejection fraction less than 40%.
Korábbi kezelés
People taking Dabigatran cannot join unless they first had idarucizumab.
Biomarker vagy leletérték
Blood troponin I more than 14 pg/mL if under 75 years, or more than 45 pg/mL if 75 years or older. Women who can have children need a negative pregnancy test.

A részvétel fő kizáró okai

  • High-risk pulmonary embolism with unstable blood pressure and circulation.
  • Higher risk of bleeding, such as major bleeding in the last 6 months or any past bleeding in the brain.
  • Major surgery or major injury in the last 4 weeks, or brain or spine surgery in the last 2 months.
  • Pregnancy or breastfeeding.
  • Known allergy to non-immunogenic recombinant staphylokinase.

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Men and women aged 18 and over
  • Verified diagnosis of intermediate high-risk PE using CTPA, no more than two weeks from the symptoms onset
  • RV dysfunction, defined as a RV/LV ventricular end-diastolic diameter ratio more than 1.0 assessed by CTPA
  • Increased risk of early death or hemodynamic collapse, defined by one of the following criteria:; systolic blood pressure less than 110 mm Hg, but not less than 90 mm Hg for more than 15 minutes; respiratory rate more than 20 per minute or SpO2 less than 90% without oxygen support; chronic heart failure with left ventricular ejection fraction less than 40%
  • Serum troponin I level more than 14 pg/mL in patients under 75 years, and more than 45 pg/mL in patients aged 75 years or older
  • Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:; women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year); men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)
  • Availability of signed and dated informed consent of the patient to participate in the study

Ki nem vehet részt

  • Increased risk of bleeding:; extensive bleeding at present or within the previous 6 months; intracranial (including subarachnoid) hemorrhage at present or in history; hemorrhagic stroke within the last 6 months; a history of diseases of the central nervous system (including neoplasms, aneurysms); intracranial or spinal surgical interventions within the last 2 months; major surgery or major trauma within the previous 4 weeks; recent puncture of an incompressible blood vessel (eg, subclavian or jugular vein); severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis; confirmed gastric or duodenal ulcer within the last 3 months; neoplasm with an increased risk of bleeding; simultaneous administration of Dabigatran without prior administration of idarucizumab; arterial aneurysms, developmental defects of arteries / veins; acute pancreatitis; bacterial endocarditis, pericarditis; suspicion of aortic dissecting aneurysm; any other conditions, in the opinion of the investigator, associated with a high risk of bleeding
  • Known hypersensitivity to the non-immunogenic recombinant staphylokinase
  • High-risk PE with hemodynamic instability
  • Lactation, pregnancy

Ez a vizsgálat jelenleg itt érhető el: Oroszország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Objective: to evaluate the efficacy and safety of the non-immunogenic recombinant staphylokinase with its single bolus administration in comparison with placebo in normotensive patients with intermediate high-risk pulmonary embolism (PE)

A vizsgálat 2 csoportja

  • Non-immunogenic recombinant staphylokinaseA vizsgált kezelés

    lyophilisate for preparation of a solution for intravenous administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, intravenously as a quick single bolus injection for 10-15 seconds, regardless of body weight.

  • PlaceboPlacebo, összehasonlításként

    15 mg of placebo reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the Efficacy and Safety of a Single Bolus Administration of Non-immunogenic Recombinant Staphylokinase in Patients With Intermediate High-risk Pulmonary Embolism (FORPE-2)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2025. december 5.